Group 1 - The company, Zhongsheng Pharmaceutical, announced the convening of its 27th meeting of the 8th Board of Directors on September 18, 2025, to discuss the proposal regarding the use of part of the idle raised funds for cash management [1] - The meeting was held both in-person and via communication voting [1]

核查意见 华泰联合证券有限责任公司 关于广东众生药业股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为广东众生药业股份有限公司（以下简称"众生药业"或"公司"）2022年向 特定对象发行股票并在主板上市的保荐机构，根据《证券发行上市保荐业务管理 办法》《上市公司募集资金监管规则》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》及《深圳 证券交易所上市公司自律监管指引第13号——保荐业务》等相关法律法规和规范 性文件的规定，对公司使用闲置募集资金进行现金管理事项进行了审慎尽职调查， 具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意广东众生药业股份有限公司向特定对 象发行股票注册的批复》（证监许可〔2023〕891号）同意，公司向12名特定对 象发行人民币普通股（A股）38,969,401股，发行价格为15.36元/股，实际募集资 金总额为598,569,999.36元，扣除各项发行费用8,373,028.97元（不含税）后，募 集资金净额为590,196 ...

证券代码：002317 公告编号：2025-098 广东众生药业股份有限公司 关于公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第八届董事会第二十次会议及于 2025 年 5 月 19 日召开的 2024 年年度股东大会 审议通过了《关于公司向合并报表范围内子公司提供担保额度的议案》，为统筹 安排子公司（指"公司合并报表范围内的子公司"，下同）的生产经营活动，确 保子公司的生产经营持续发展，提高资金使用效率，公司继续为子公司向银行申 请信贷业务提供合计不超过人民币 20 亿元额度的连带责任保证。授权董事长在 上述额度内根据具体情况实施相关事宜并签署有关文件。 具体内容详见公司于 2025 年 4 月 26 日及 2025 年 5 月 20 日刊载在《证券时 报》和巨潮资讯网（www.cninfo.com.cn）的相关公告。 公司根据上述事项分别与招商银行、交通银行签署了《最高额不可撤销担保 书》《保证合同》。公司为华南药业向招 ...

证券代码：002317 公告编号：2025-097 广东众生药业股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 9 月 18 日召开 了第八届董事会第二十七次会议及第八届监事会第二十七次会议，审议通过了 《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募 集资金投资计划正常进行的情况下，使用不超过人民币 18,000.00 万元的闲置募 集资金进行现金管理，适时购买结构性存款、大额存单等安全性高的保本型产品。 现金管理期限为本次董事会审议通过之日起十二个月内。在上述额度和期限 内资金可滚动使用，但在任一时点的实际投资金额不超过人民币 18,000.00 万元， 本次使用部分闲置募集资金进行现金管理事项将在上述额度内，授权董事长具体 实施相关事宜。 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》等相关规定，本事项属于公司董事会审批权限范围，无需提交公司股东大 会审议。现将具体情况公告如下： 一 ...

证券代码：002317 公告编号：2025-096 一、审议通过了《关于使用部分闲置募集资金进行现金管理的议案》。 广东众生药业股份有限公司 第八届监事会第二十七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届监事会第二十七次 会议的会议通知于 2025 年 9 月 12 日以专人形式送达全体监事，会议于 2025 年 9 月 18 日在公司会议室以现场和通讯表决方式召开。本次会议应出席监事 3 人， 实际出席监事 3 人，会议由公司监事会主席谭珍友先生主持，董事会秘书列席本 次会议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。经 与会监事认真审议，以记名投票方式表决，做出如下决议： 广东众生药业股份有限公司监事会 二〇二五年九月十八日 第 1页 共 1页 经审核，监事会认为公司使用部分暂时闲置募集资金进行现金管理履行了必 要的审批程序，内容及程序符合募集资金使用的相关规定，有利于提高募集资金 使用效率，获得一定的投资收益，不影响募集资金投资项目的正常运行，不存在 变相改变募集资 ...

证券代码：002317 公告编号：2025-095 广东众生药业股份有限公司 第八届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十七次 会议的会议通知于 2025 年 9 月 12 日以专人形式送达全体董事，会议于 2025 年 9 月 18 日在公司会议室以现场和通讯表决方式召开。本次会议应出席董事 9 人， 实际出席董事 9 人。会议由公司董事长陈永红先生主持，全体监事、董事会秘书 列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。 经与会董事认真审议，以记名投票方式表决，做出如下决议： 一、审议通过了《关于使用部分闲置募集资金进行现金管理的议案》。 为提高募集资金使用效率，增加资金收益，公司在确保不影响募集资金投资 计划正常进行的情况下，拟使用不超过人民币 18,000.00 万元的闲置募集资金进 行现金管理，适时购买结构性存款、大额存单等安全性高的保本型产品。 现金管理期限为本次董事会审议通过之日起十二个月内。在上述额度和期限 内资金可滚动 ...

证券之星消息，9月18日中药板块较上一交易日下跌0.74%，维康药业领跌。当日上证指数报收于 3831.66，下跌1.15%。深证成指报收于13075.66，下跌1.06%。中药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日中药板块主力资金净流出4.56亿元，游资资金净流入1.93亿元，散户资金净流入 2.63亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300158 振东制药 | | 7468.12万 | 12.28% | 307.26万 | 0.51% | -7775.39万 | -12.79% | | 002317 | 众生药业 | 4981.74万 | 5.33% | -3446.28万 | -3.68% | -1535.47万 | -1.64% | ...

Company Overview - Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan, Guangdong Province, established on December 31, 2001, and listed on December 11, 2009. The company focuses on the research, production, and sales of pharmaceuticals [1]. - The main business revenue composition includes: Traditional Chinese Medicine sales 53.03%, chemical drug sales 38.12%, Chinese medicinal materials and decoction pieces sales 6.13%, raw materials and intermediates sales 2.14%, and others 0.58% [1]. Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical achieved operating revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%. However, the net profit attributable to the parent company was 188 million yuan, showing a significant year-on-year increase of 114.96% [2]. - Since its A-share listing, the company has distributed a total of 2.019 billion yuan in dividends, with 502 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 18, the stock price of Zhongsheng Pharmaceutical increased by 2.19%, reaching 20.54 yuan per share, with a total market capitalization of 17.458 billion yuan [1]. - The stock has seen a year-to-date increase of 71.88%, with a recent 5-day increase of 1.68%, a 20-day decrease of 8.95%, and a 60-day increase of 36.48% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 29, where it recorded a net purchase of 181 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 89,900, a decrease of 1.32% from the previous period, with an average of 8,470 circulating shares per person, an increase of 1.33% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 9.1731 million shares, while other notable shareholders include Xingquan He Feng Mixed Fund and Xingquan Multi-Dimensional Value Mixed Fund, which have reduced their holdings [3].

Core Insights - On September 17, Zhongsheng Pharmaceutical experienced a decline of 0.45% with a trading volume of 531 million yuan, indicating a slight decrease in market performance [1] - As of June 30, 2025, Zhongsheng Pharmaceutical reported a revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%, while net profit attributable to shareholders increased by 114.96% to 188 million yuan [2] Financing and Margin Trading - On September 17, the financing buy-in amount for Zhongsheng Pharmaceutical was 50.95 million yuan, with a net financing outflow of 2.53 million yuan, indicating a higher level of financing activity [1] - The total margin trading balance for Zhongsheng Pharmaceutical reached 553 million yuan, accounting for 3.22% of its market capitalization, which is above the 70th percentile of the past year [1] Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders for Zhongsheng Pharmaceutical was 89,900, a decrease of 1.32% from the previous period, while the average number of circulating shares per person increased by 1.33% to 8,470 shares [2] - The company has distributed a total of 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 9.1731 million shares, marking its entry as a new shareholder [3]

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with the leading Chinese medicine ETF (560080) showing resilience despite market fluctuations, attracting significant capital inflows and demonstrating strong growth potential in the context of regulatory changes and industry innovation efforts [1][4][6]. Market Performance - The Chinese medicine ETF (560080) recorded a slight decline but maintained a premium throughout the day, with a trading volume exceeding 71 million yuan. Over the past 10 days, it has seen net inflows on 9 occasions, totaling over 150 million yuan, and its latest scale has surpassed 2.4 billion yuan, leading its peers [1][4]. - Major components of the ETF index mostly experienced pullbacks, with Renhe Pharmaceutical declining over 1%, while Panlong Pharmaceutical rose over 1% [3][5]. Financing and Investment Trends - Leveraged funds are increasingly utilizing the ETF to invest in the high-value Chinese medicine consumer sector, with the latest financing balance approaching 80 million yuan and a financing buy-in amount exceeding 12 million yuan as of September 16, 2025 [4]. - The Chinese medicine industry is viewed as having stable cash flow and high dividends, with companies like Huaren Sanjiu and Jiangzhong Pharmaceutical showing strong performance in their incentive plans, which are expected to drive new growth [7][8]. Regulatory Developments - The National Medical Products Administration has announced new regulations for Chinese medicine production supervision, effective March 1, 2026, emphasizing quality control throughout the entire production process [5]. Innovation and Growth Strategies - Chinese medicine companies are actively pursuing innovation and transformation into chemical and biological pharmaceuticals through self-research, mergers and acquisitions, and strategic partnerships, aiming to create a second growth curve [6]. - The industry is expected to see improved performance in the second half of 2025, driven by reduced cost pressures from declining raw material prices and enhanced operational efficiencies [7][9]. Dividend and Profitability Insights - A significant number of central state-owned enterprises in the Chinese medicine sector are projected to have dividend yields exceeding 3% in 2024, with Jiangzhong Pharmaceutical and Dong'e Ejiao leading in dividend rates [8][9]. - Despite facing growth pressures in the first half of 2025, many companies have managed to achieve positive growth in net profit through quality improvement and efficiency enhancement strategies [9]. Market Sentiment and Future Outlook - The Chinese medicine index is gradually recovering, with institutional holdings remaining light. The sector is expected to attract more capital as it combines attributes of new consumer demand and pharmaceutical needs [10][12].